Orticumab

Tax included
Orticumab (MLDL1278A) is an antibody targeting to oxidized or malondialdehyde-modified lipoprotein (LDL). Orticumab specifically inhibits oxidized low-density lipoproteins (oxLDL). Orticumab involves in modulation of autoimmune responses against oxLDL, improves atherosclerosis in animal model. Orticumab also can be used for research of psoriasis improvement.
MedChemExpress 
HY-P99793

Data sheet

Size
Multiple sizes
Reactivity
LDLR
Application
COVID-19-immunoregulation
CAS
1314241-10-5